Application of Recombinant DNA Biotechnology: Development of Covid-19 Vaccine
DOI:
https://doi.org/10.53089/medula.v11i3.177Keywords:
covid 19, DNA recombinant, DNA vaccineAbstract
The role of science and technology in all sectors is getting bigger and bigger. The development of science and technology encourages innovation in all fields including in the health sector. Specifically regarding advances in science and technology in the health sector, it relies on research by experts, including medical biotechnology. One form of utilization of medical biotechnology is the development of vaccinations. In dealing with the Covid-19 pandemic, the application of medical biotechnology can be done by developing vaccinations using recombinant DNA technology. All researchers around the world in all related fields such as genomic and structural biology experts work together to develop this vaccine. Of these several agencies, InoVio as one of the research agencies developed a DNA vaccine. The DNA vaccine has several advantages, including fast production time and formulation, can be produced in large quantities, is safer, more stable to temperature so that it is easy to store and transport. Currently the DNA vaccine for the SARS-CoV-2 virus is still in the next clinical trial phase and is mass produced for emergency use.The role of science and technology in all sectors is getting bigger and bigger. The development of science and technology encourages innovation in all fields including in the health sector. Specifically regarding advances in science and technology in the health sector, it relies on research by experts, including medical biotechnology. One form of utilization of medical biotechnology is the development of vaccinations. In dealing with the Covid-19 pandemic, the application of medical biotechnology can be done by developing vaccinations using recombinant DNA technology. All researchers around the world in all related fields such as genomic and structural biology experts work together to develop this vaccine. Of these several agencies, InoVio as one of the research agencies developed a DNA vaccine. The DNA vaccine has several advantages, including fast production time and formulation, can be produced in large quantities, is safer, more stable to temperature so that it is easy to store and transport. Currently the DNA vaccine for the SARS-CoV-2 virus is still in the next clinical trial phase and is mass produced for emergency use.
References
Ceraolo C, Giorgi FM. Genomic Variance of
The 2019-nCoV Coronavirus. J med virol
Zhou P, Yang X, Wang X, et al. a Pneumonia
Outbreak Associated with a New
Coronavirus of Probable Bat Origin. Nature;
: 270-273.
World Health Organization. Novel
Coronavirus (Covid-19) Situation Report.
Available from: https://www.who.int/
docs/default-source/coronavirus/situationreport/
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al.
Genomic Characterisation And Epidemiology
of 2019 Novel Coronavirus: Implications for
Virus Origin and Receptor Binding. Lancet;
: 565-74.
Gao K, Wang R. Machine Intellegence
Design of 2019-nCoV Drugs. bioRxiv.
available from: https;//www.biorxiv.org/
content/10.1101./2020.01.30.927889v1.full.
pdf+html,
Hesty W, Ika N. Bioteknologi
ImperialismeModal &Kejahatan Global.
Insist Press; Yogyakarta: 2003.
Griffiths AJF, Gelbart WM, Miller JH,
Lewontin RC. Modern Genetic Analysis.
W.H. Freeman Company; New York: 1999.
Wong DWS. The ABC of Gene Cloning.
International Thomson Publishing.
NewYork; 2007: 213.
Nascimento, IP, Leite LCC. Recombinant
Vaccines and The Development of New
Vaccine Strategies. Braz J Med Biol Res.
: 45(12):1102-1111.
Retnoningrum, Debbie S. Prinsip Teknologi
DNA Rekombinan. Sekolah Farmasi ITB.
Bioteknologi Farmasi-FA. Bandung; 2010.
Girard MP, U Fruth, MP Kieny. A review of
Vaccine Research and Development:
Tuberculosis. Vaccine. 2005: 5725-5731.
Leonardi S, S Spina, L Spicuzza,N Rotolo N,
M La Rosa. Hepatitis B vaccination failure
inceliac disease: is there a need toreassess
current immunizationstrategies?
Vaccine.2009; 27(43): 6030-3.
Du X, J Wang , Y Kang, W Xiao, G Zhao, B
Wang. Suppression of the antigen-specific T
cellimmune response by co-immunization
with the HBV DNA vaccine and recombinant
HBsAg.Acta Microbiologica Sinica. 2009; 49:
-942.
Wolff JA, JJ Ludtke, G Acsadi, PWilliams, A
Jani. Longterm persistence of plasmidDNA
and foreign gene expression in mouse
muscle. Hum MolGen. 1992: 363-369.
Robinson HL, LA Hunt, RG Webster.
Protection against a lethal influenza virus
challenge by immunization with expressing
plasmid DNA. Vaccine. 1993: 957-960.
Liu M, B Acres, JM Balloul, N Bizouarne, P
Slos, et al. Gene-based vaccines and
immunotherapeutics. Proc Natl Acad Sci.
USA; 2004: 145-171.
Glenting J, S Wessel. Ensuring safety of DNA
Vaccines. Microbial Cell Factorie; 2005: 26.
Martin JE, NJ Sulivan, ME Enama, RA Koup,
et al. A DNA Vaccine for Ebola Virus is safe
and immunogenic in a phase I clinical trials.
Clin Vaccine Immunol; 2006: 1267-1277.
Corum, J., Denise G., Carl Z. Corona Virus
Tracker. The New York Times. 2020.
Available from: https://www.nytimes.com/
interactive/2020/science/coronavirusvaccine-
tracker.html
Gao, Q., Linlin B., Haiyan M., Lin, W, et al.
Rapid Development of an Inactivated
Vaccine Candidate for SARS-CoV-2. Science.
Available from: https://doi.org/
1126/science.abc1932.
Inovio Pharmaceuticals. Inovio to begin
dosing n trial of INO-4800 DNA Vaccine
Candidate for COVID-19. 2020. Available
from:
https://www.firstwordpharma.com/node/1
Zhu, FC., Yu Hua., Xu Hua., Li Hua., Wen
Juan., Jing Hin et al. Safety, Tolerability and
Immunogenicity of Recombinant Adenovirus
Type-5 Vactored COVID-19 Vaccine: A Dose
Escalation, Open Label, Non Randomized,
First in Human Trial. Elsevier. 2020;
Available from: https://doi.org/10.1016.
S0140-6736(20)31208-3.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
